Ionis Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.09 Per Share (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities research analysts at Leerink Partnrs raised their FY2026 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a report released on Tuesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of $1.09 per share for the year, up from their previous forecast of $1.04. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($4.00) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2027 earnings at $1.56 EPS.

A number of other research analysts have also weighed in on the company. JPMorgan Chase & Co. increased their price target on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. Wolfe Research upgraded Ionis Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $58.00 price objective for the company in a report on Wednesday, April 10th. Bank of America upgraded Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $52.00 to $62.00 in a report on Tuesday, January 2nd. Oppenheimer increased their price target on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an “outperform” rating in a report on Tuesday, April 9th. Finally, Royal Bank of Canada increased their price target on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $56.08.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $40.91 on Wednesday. Ionis Pharmaceuticals has a 1 year low of $34.32 and a 1 year high of $54.44. The firm has a market cap of $5.96 billion, a P/E ratio of -15.98 and a beta of 0.39. The stock’s 50 day moving average price is $44.25 and its 200 day moving average price is $47.35. The company has a debt-to-equity ratio of 3.18, a quick ratio of 5.83 and a current ratio of 5.90.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The firm had revenue of $325.00 million for the quarter, compared to analyst estimates of $176.01 million. During the same quarter in the prior year, the company earned ($0.37) EPS. Ionis Pharmaceuticals’s revenue was up 113.8% on a year-over-year basis.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the transaction, the executive vice president now owns 19,631 shares of the company’s stock, valued at $816,649.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the sale, the executive vice president now owns 19,631 shares in the company, valued at $816,649.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Swayze sold 1,907 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $49.56, for a total transaction of $94,510.92. Following the completion of the sale, the executive vice president now owns 34,324 shares in the company, valued at approximately $1,701,097.44. The disclosure for this sale can be found here. Insiders have sold 51,434 shares of company stock valued at $2,556,127 over the last quarter. Insiders own 2.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP grew its position in Ionis Pharmaceuticals by 162.2% in the fourth quarter. Wellington Management Group LLP now owns 4,616,978 shares of the company’s stock worth $233,573,000 after buying an additional 2,856,353 shares during the last quarter. Norges Bank acquired a new position in Ionis Pharmaceuticals in the fourth quarter worth approximately $48,974,000. Adage Capital Partners GP L.L.C. acquired a new position in Ionis Pharmaceuticals in the third quarter worth approximately $48,399,000. Woodline Partners LP acquired a new position in Ionis Pharmaceuticals in the second quarter worth approximately $42,750,000. Finally, Point72 Asset Management L.P. boosted its stake in Ionis Pharmaceuticals by 584.7% in the 4th quarter. Point72 Asset Management L.P. now owns 968,800 shares of the company’s stock worth $49,012,000 after purchasing an additional 827,300 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.